CureVac (NASDAQ:CVAC) Shares Gap Down – Should You Sell?

CureVac (NASDAQ:CVAC)’s share price gapped down prior to trading on Friday . The stock had previously closed at $3.20, but opened at $3.13. CureVac shares last traded at $3.14, with a volume of 99,760 shares traded.

Analyst Upgrades and Downgrades

Separately, JMP Securities reaffirmed a “market outperform” rating and issued a $16.00 price objective on shares of CureVac in a research report on Friday, February 14th.

CureVac Stock Performance

The company has a debt-to-equity ratio of 0.05, a quick ratio of 6.19 and a current ratio of 6.20. The firm’s 50 day simple moving average is $3.66 and its 200 day simple moving average is $3.20. The firm has a market capitalization of $680.60 million, a price-to-earnings ratio of 5.53 and a beta of 2.53.

Institutional Trading of CureVac

Institutional investors and hedge funds have recently bought and sold shares of the business. Private Advisor Group LLC purchased a new stake in CureVac during the third quarter worth $30,000. International Assets Investment Management LLC purchased a new position in CureVac during the third quarter valued at $35,000. Integrated Wealth Concepts LLC purchased a new position in CureVac during the third quarter valued at $35,000. Jane Street Group LLC raised its position in shares of CureVac by 239.0% in the third quarter. Jane Street Group LLC now owns 79,247 shares of the company’s stock valued at $235,000 after buying an additional 55,867 shares during the last quarter. Finally, Public Employees Retirement System of Ohio acquired a new stake in shares of CureVac in the third quarter valued at about $91,000. 17.26% of the stock is currently owned by institutional investors and hedge funds.

CureVac Company Profile

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.